Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer
Executive Summary
Merck’s Keytruda improved progression-free survival and overall survival in previously untreated non-small cell lung cancer patients in the highly-anticipated KEYNOTE-024 trial, all but guaranteeing a rapid FDA approval in the indication.
You may also be interested in...
Was PD-L1 Test To Blame For Failure Of Bristol's Opdivo In '026 Trial?
NEJM editorial suggests that differences in PD-L1 testing may explain why Bristol's Opdivo failed in first-line lung cancer trial whereas Merck's Keytruda succeeded, but some analysts aren't so sure.
Was PD-L1 Test To Blame For Failure Of Bristol's Opdivo In '026 Trial?
NEJM editorial suggests that differences in PD-L1 testing may explain why Bristol's Opdivo failed in first-line lung cancer trial whereas Merck's Keytruda succeeded, but some analysts aren't so sure.
It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer
The event that the oncology market has been waiting for has arrived. FDA approved Merck’s PD-1 inhibitor Keytruda for first-line treatment of non-small cell lung cancer, a paradigm-changing event that opens up the largest sales segment for immuno-oncology.